<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Altimmune, Inc.

    Altimmune, Inc.

    Altimmune is a clinical-stage immunotherapeutics company focused on the developmen...

    Altimmune is a clinical-stage immunotherapeutic...

    Filing Type:    PU
    CrowdMed, Inc.

    CrowdMed, Inc.

    CrowdMed’s patented prediction market technology can uncover diagnoses to real-w...

    CrowdMed’s patented prediction market technol...

    Amount Raised:    $3,100,000.00
    Fundraising Status:    SD
    Filing Type:    CF
    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing a...

    Supernus Pharmaceuticals, Inc. is a pharmaceuti...

    Filing Type:    PU
    Applied Science Products, Inc.

    Applied Science Products, Inc.

    Applied Science Products operates Advanced Plasma Products, Inc., a science and en...

    Applied Science Products operates Advanced Plas...

    DarioHealth Corp.

    DarioHealth Corp.

    DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) co...

    DarioHealth Corp. (NASDAQ: DRIO) is a leading g...

    Filing Type:    PU
    Cancer Genetics, Inc.

    Cancer Genetics, Inc.

    Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...

    Cancer Genetics, Inc. is an emerging leader in ...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    INmune Bio Inc.

    INmune Bio Inc.

    INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...

    INmune Bio Inc. is a clinical stage biotechnolo...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    NeoGenomics, Inc.

    NeoGenomics, Inc.

    NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and phar...

    NeoGenomics, Inc. is a high-complexity CLIA-cer...

    Filing Type:    PU
    UroGen Pharma Ltd.

    UroGen Pharma Ltd.

    UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company developing advanc...

    UroGen Pharma Ltd. is a clinical-stage biopharm...

    Filing Type:    PU
    Anchiano Therapeutics Ltd.

    Anchiano Therapeutics Ltd.

    We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...

    We are Anchiano Therapeutics, a pivotal-stage b...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.